<DOC>
	<DOCNO>NCT00541385</DOCNO>
	<brief_summary>- The primary objective clinical study demonstrate efficacy fix combination pyronaridine artesunate granule formulation ( 60:20 mg ; paediatric PYRAMAX® ) show PCR-corrected adequate clinical parasitological cure rate 90 % . - Treatment success failure classify accord WHO Guidelines 2005</brief_summary>
	<brief_title>Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets P. Falciparum Malaria Pediatric Patients</brief_title>
	<detailed_description>The need safe efficacious anti-malarial treatment infants child huge give major group affect acute uncomplicated malaria . There relatively paediatric formulation artemisinin combination therapy . In addition tablet formulation pyronaridine artesunate ( PA ) ( PYRAMAX ) , Shin Poong Pharm Co develop paediatric dose form present granule formulation , pack appropriate aluminium sachet contain 60mg pyronaridine tetraphosphate 20mg artesunate . This Phase III study design demonstrate efficacy PA granule formulation , assess term PCR-corrected APCR , 90 % subsequently compare ( non-inferiority ) efficacy safety PA granule formulation Coartem® crush tablet infant child .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Pyronaridine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>1 . Male female patient ≤12 year age . 2 . Body weight ≥ 5 kg &lt; 25 kg clinical evidence severe malnutrition ( defined child whose weightforheight 3 standard deviation less 70 % median NCHS/WHO normalise reference value ) . 3 . Presence acute uncomplicated P. falciparum monoinfection confirm : 1 . Fever , define axillary temperature ≥ 37.5°C oral/tympanic/rectal temperature ≥ 38°C , document history fever previous 24 hour , 2 . Positive microscopy P. falciparum parasite density 1,000 200,000 asexual parasite count/µl blood . 4 . Written informed consent , accordance local practice , provide parent/guardian . If parent/guardian unable write , witness consent permit accord local ethical consideration . Where possible , patient assent seek . 5 . Ability swallow whole volume liquid medication suspend . 6 . Female patient childbearing potential must neither pregnant ( demonstrated negative pregnancy test ) lactating , must willing take measure become pregnant study period . 7 . Ability willingness participate base information give parent guardian access health facility . The patient comply schedule follow visit D42 . 1 . Patients sign symptom severe/complicated malaria require parenteral treatment accord World Health Organization Criteria 2000 [ Attachment 3 ] . 2 . Mixed Plasmodium infection . 3 . Severe vomiting , define three time 24 hour prior inclusion study inability tolerate oral treatment , severe diarrhoea define 3 watery stool per day . 4 . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , QTc interval great equal 450 millisecond ) , respiratory ( include active tuberculosis ) , history jaundice , hepatic , renal , gastrointestinal , immunological ( include active HIVAIDS ) , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric , history convulsion abnormality ( include recent head trauma ) . 5 . Presence significant anaemia , define Hb &lt; 8 g/dL . 6 . Presence febrile condition cause disease malaria . 7 . Known history hypersensitivity , allergic adverse reaction pyronaridine , lumefantrine artesunate artemisinins . 8 . Patients known disturbance electrolytes balance , e.g. , hypokalaemia hypomagnesaemia . 9 . Use antimalarial agent within 2 week prior start study evidence report patient history . 10 . Pregnant breast feeding . 11 . Patients take drug metabolise cytochrome enzyme CYP2D6 ( flecainide , metoprol , imipramine , amitriptyline , clomipramine ) . 12 . Received investigational drug within past 4 week . 13 . Known active Hepatitis A IgM ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) . 14 . Known positive HIV antibody . 15 . Liver function test [ ASAT/ALAT level ] 2.5 time upper limit normal range . 16 . Known significant renal impairment indicate serum creatinine 1.4 mg/dL . 17 . Previous participation clinical study pyronaridine artesunate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>malaria</keyword>
	<keyword>pediatric</keyword>
	<keyword>Africa</keyword>
	<keyword>Phillipines</keyword>
	<keyword>Coartem</keyword>
	<keyword>Artesunate</keyword>
	<keyword>lumefantrine</keyword>
	<keyword>Arthemeter</keyword>
	<keyword>pyronaridine</keyword>
	<keyword>Pyramax</keyword>
</DOC>